Hergen Spits

7964406, Jun 21, 2011

Aug 10, 2005

11/659921

Hergen Spits - San Francisco CA, US
Benjamin Berkhout - Naarden, NL
Jurgen E. Seppen - Naarden, NL
David M. Markusic - Amsterdam, NL
Kees Weijer - Amsterdam, NL

Academisch Medisch Centrum Bij De Universiteit Van Amsterdam - Amsterdam

C12N 15/63
C12N 15/06
C12N 5/08

435455, 435326, 435372

The invention provides a method for producing a stabilized cell of interest, said method comprising providing a stem cell and/or a precursor cell of said cell of interest with a nucleic acid sequence which, when present in said cell of interest, is capable of stabilizing said cell of interest, providing a non-human animal with said stem cell and/or precursor cell, allowing generation of said cell of interest in said animal, and obtaining said cell of interest. Said animal is preferably provided with a human stem cell and/or human precursor cell, allowing production of a human cell line.

8562996, Oct 22, 2013

May 30, 2008

12/600950

Hergen Spits - San Mateo CA, US
Tim Beaumont - Amstel, NL

MedImmune Limited - Cambridge

A61K 39/42
A61K 39/155
C12P 21/00

4241591, 4242111, 435 691

The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, and means and methods for producing them.

20090217403, Aug 27, 2009

Jun 6, 2006

11/921925

Hergen Spits - San Francisco CA, US

A01K 67/027
C12N 5/10
C12N 5/08
C40B 40/02
C40B 30/04
A61K 48/00

800 18, 800 14, 435455, 435366, 506 14, 506 9, 424 9321

The invention provides a method for generating a T cell comprising a T cell receptor capable of specifically binding an antigen of interest, comprising: —providing a hematopoietic stem cell and/or a precursor cell of a T cell with a nucleic acid sequence comprising at least part of a rearranged gene encoding a TCR chain, or a functional equivalent thereof; and—allowing for differentiation of said stem cell and/or precursor cell and generation of at least one T cell derived from said stem cell and/or precursor cell.

20100093038, Apr 15, 2010

Dec 9, 2005

12/086269

Hergen Spits - San Mateo CA, US

Academisch Medisch Centrum bij de Universiteit van Amsterdam - Amsterdam
AIMM Therapeutics B.V. - Amsterdam

C12P 21/00
C12N 5/16
C07K 16/00

435 711, 435326, 5303871

The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.

20100113745, May 6, 2010

Dec 8, 2006

12/086328

Hergen Spits - San Mateo CA, US
Ferenc A. Scheeren - Kaatsheuvel, NL
Sean A. Diehl - Haarlem, NL

Meibergdreef 9 - Amsterdam

C07K 16/00
C12N 5/07
C12N 7/00
C12Q 1/70
C12P 21/06

5303871, 435326, 4352351, 435 5, 435 696

The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.

57764514, Jul 7, 1998

Jul 5, 1994

8/270805

Kevin W. Moore - Palo Alto CA
Hergen Spits - Palo Alto CA

Schering Corporation - Kenilworth NJ

A61K 4505

424 852

A method is provided for using interleukin-10 in adoptive immunotherapy of cancer. A population of tumor-infiltrating lymphocytes (TILs) are expanded in culture in the presence of interleukin-2 (IL-2) and interleukin-10 (IL-10). After administration of the TILs to a patient, effective amounts of both IL-2 and IL-10 are administered to enhance the tumor cell cytoxicity of the TILs and to reduce side effects caused by IL-2-induced cytokine production in the TILs and other cells of the patient.

58339760, Nov 10, 1998

Mar 24, 1995

8/410654

Rene de Waal Malefyt - Mountain View CA
Maureen Howard - Los Altos Hills CA
Hiroshi Ishida - Wakayama, JP
Anne O'Garra - Pala Alto CA
Hergen Spits - Los Altos CA
Albert Zlotnik - Palo Alto CA

Schering Corporation - Kenilworth NJ

A61K 3820

424 852

A method is provided for treating septic shock or toxic shock that comprises administering an effective amount of interleukin-10.